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Abstract
Background Women may be at increased risk for venous thromboembolism (VTE) as compared with
men. We studied the effects of genetic and biochemical markers of thrombophilia in women, in
conjunction with other established risk factors for VTE.
Method The present retrospective case–control study was conducted in a thrombosis treatment
programme at a large Toronto hospital. The cases were 129 women aged 16–79 years with
objectively confirmed VTE. Age-matched control individuals were women who were free of venous
thrombosis. Neither cases nor control individuals had known cardiovascular disease. Participants were
interviewed regarding personal risk factors for VTE, including smoking, history of malignancy,
pregnancy, and oestrogen or oral contraceptive use. Blood specimens were analyzed for common
single nucleotide polymorphisms of prothrombin, factor V and methylenetetrahydrofolate reductase
(MTHFR; C677T, A1298C and T1317C), and the A66G polymorphism for methionine synthase
reductase (MTRR). Fasting plasma homocysteine was also analyzed.
Results Women with VTE were significantly more likely than female control individuals to carry the
prothrombin polymorphism and the factor V polymorphism, or to have fasting hyperhomocysteinaemia.
Homozygosity for the C677T MTHFR gene was not a significant risk factor for VTE, or were the
A1298C or T1317C MTHFR homozygous variants. Also, the A66G MTRR homozygous state did not
confer an increased risk for VTE.
Conclusion Prothrombin and factor V polymorphisms increased the risk for VTE in women,
independent from other established risk factors. Although hyperhomocysteinaemia also heightens this
risk, common polymorphisms in two genes that are responsible for homocysteine remethylation do not.
These findings are consistent with previous studies that included both men and women.
Keywords case–control study, deep vein thrombosis, factor V gene, folate, genetics, homocysteine, methionine
synthase reductase, methylenetetrahydrofolate reductase, prothrombin gene, pulmonary embolism, risk,
thrombophilia, venous thromboembolism, women’s health
CI = confidence interval; MTHFR = methylenetetrahydrofolate reductase; MTRR = methionine synthase reductase; OR = odds ratio; RH = relative
hazard; tHcy = total homocysteine; VTE = venous thromboembolism.
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Introduction
The development of both idiopathic and situational VTE
remains multifactorial [1]. Advanced age [2], malignancy
[1] and smoking [3], in addition to both genetic and bio-
chemical abnormalities within the coagulation and
endovascular systems [4], predispose to VTE. Further-
more, women are perceived to be at greater risk for VTE
[2,5], principally due to the presence of both endogenous
and exogenous oestrogen sources [6–9].
Published data implicate both the guanine-to-adenine
nucleotide 20210 (G20210A) prothrombin and guanine-
to-adenine nucleotide 1691 (G1691A) factor V gene poly-
morphisms in the development of VTE during pregnancy
and the puerperium [10,11]. Few studies have assessed
these and other genetic risk factors, as well as hyperhomo-
cysteinaemia, among nonpregnant women, while also
considering such elements as smoking [3], malignancy [1],
oestrogen use [6] and recent immobilization [12].
In order to better define the role of thrombophilic defects
and other risk factors in the development of VTE in
women, we conducted the present study. In addition to
probable genetic risk factors [10,11] and total homocys-
teine (tHcy) levels, we examined the relationship between
VTE and four polymorphisms involved in tHcy remethyla-
tion to methionine. The first two, the adenine-to-cytosine
(A1298C) and thymine-to-cytosine (T1317C) [13], which
are MTHFR polymorphisms, participate in the cycling of
folate coenzyme by the MTHFR enzyme, in addition to the
classic MTHFR cytosine-to-thymine (C677T) polymor-
phism [14]. We also studied the effect of the novel
adenine-to-guanine polymorphism (A66G) in MTRR, the
cobalamin-dependent enzyme that is responsible for
folate-dependent tHcy remethylation [14].
Method
We conducted a retrospective case–control study. Eligi-
ble cases included all women aged 16–79 years with
objectively confirmed VTE seen at the University Health
Network in Toronto from April 1996 to October 1999.
Objective diagnostic testing comprised compression ultra-
sonography or venography for deep vein thrombosis of the
limb, ventilation/perfusion or contrast enhanced spiral
computed tomography imaging for pulmonary embolism,
and magnetic resonance or computed tomography
imaging for intra-abdominal or intracranial venous throm-
bosis. We excluded those women whose VTE was related
to a central venous catheter [15], as well as those with a
history of coronary artery, cerebrovascular or peripheral
vascular disease [16], or a previously identified thrombo-
philia defect. After obtaining written informed consent, one
female control individual (within 10 years of age) was
matched to every case; these control individuals were
derived from a cohort of healthy women recruited through
the Family Medicine Unit at the Toronto University Health
Network. Thirty cases (approximately 25% of the study
population) had been enrolled in a previous study that
examined the relationship between hyperhomocys-
teinaemia and VTE [17], and none of the control individu-
als had participated in a previous study.
At the initial visit, a clinical nurse specialist interviewed
cases using a standardized data collection form. An
assessment for VTE risk factors included age at first VTE,
history of recurrent VTE, history of malignancy within the
past 5 years, current cigarette consumption, and immobi-
lization or surgery within 3 months before the diagnosis of
VTE. Presence of an ‘oestrogen exposure state’ was
defined as either current use of an oral contraceptive
agent, hormone replacement therapy or tamoxifen, or
being pregnant or within 6 weeks postpartum. Information
was also collected about the anatomical site of the VTE
and the method of detection. Control group data were
obtained using a standard questionnaire, administered by
a trained research assistant during a face-to-face inter-
view. The same demographic information was collected
for cases and control individuals, with the exception of a
history of recent immobilization or surgery, which was not
assessed in the control group.
All laboratory analyses were performed with the investiga-
tor blinded to each woman’s clinical diagnosis. Partici-
pants were instructed to fast for at least 8 h before plasma
tHcy specimens were collected. Neither cases nor control
individuals were known to be taking folate or vitamin B12
supplements at the time of blood specimen collection.
Plasma tHcy was analyzed using high-performance liquid
chromatography as previously described [18], and red-cell
folate was measured using a radioimmunoassay method
(Quantaphase II; Bio-Rad Laboratories Incorporated,
Toronto, Ontario, Canada). DNA was extracted from
peripheral blood cells [19]. A single multiplex polymerase
chain reaction assay was designed to identify simultane-
ously the prothrombin, factor V and MTHFR genotypes
[20–22]. The MTRR A66G genotype was analyzed as
previously described [23]. Cases (but not control individu-
als) were evaluated for the presence of anticardiolipin anti-
bodies, the lupus-like anticoagulant, and deficiencies in
protein C, protein S and antithrombin.
Statistical analysis
In the primary analysis, the association between the pres-
ence of VTE and each thrombophilic risk factor was evalu-
ated using conditional logistic regression analysis. Crude
and adjusted odds ratios (ORs) were estimated. The ORs
were adjusted for specific covariates, which were defined
a priori, including current cigarette smoking habits, oestro-
gen exposure state and recent history of cancer. Hyper-
homocysteinaemia was defined as the tHcy concentration
above the 95th centile value in the control group [24].
Interaction terms between the presence of hyperhomo-c
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cysteinaemia and the homozygous state for any MTHFR or
MTRR polymorphism were also evaluated [25].
A predefined subgroup analysis was performed excluding
cases and their respective control individuals with either
immobilization or surgery within the past 3 months, and
any case–control pairs in which either had had a malig-
nancy within the past 5 years. The potential presence of
another identifiable thrombophilia defect among the cases
(eg protein S, protein C or antithrombin deficiency) was
not accounted for in any of the analyses.
Genotype distributions and allele frequencies and equilib-
ria were analyzed using Genetic Data Analysis version 1.0
(PO Lewis and D Zaykin, 2000, Sinauer Associates, Incor-
porated, Sunderland, MA, USA). Probabilities for allele fre-
quencies were calculated using Fisher’s exact test. For
each disequilibrium (Hardy-Weinberg or pairwise linkage),
the data program estimated the probability of obtaining
the observed genotype distribution using 3600 permuted
simulations generated by an allele-shuffling algorithm.
Baseline characteristics of cases and control individuals
were compared using one-way analysis of variance for con-
tinuous variables, or the c2 test for categorical data. All
P values were two-sided, and the significance level chosen
was 0.05. Statistical analyses were performed using SAS
Version 6.12 (SAS Institute Incorporated, Cary, NC, USA).
All data were collected in an anonymous manner, and
approval to conduct the study was obtained through the
University of Toronto Research Ethics Committee.
Results
General findings
After initial review, 54 potential cases were excluded.
Reasons for exclusion included the presence of cardiovas-
cular disease (29 women), VTE related to central venous
catheters (seven women), recurrent pregnancy loss,
heparin-induced thrombocytopenia, superficial phlebitis or
cellulitis (eight women), and lack of objective evidence to
confirm the diagnosis of VTE (10 women). Thus, 129
cases, along with 129 age-matched control individuals,
were included.
Table 1 presents the characteristics of the 129 cases with
VTE and their respective control individuals. Of all
case–control pairs, 120 (93%) were matched within
7 years of age, and 82 (64%) were within 5 years. The
mean age of the cases and controls was 45.8 years and
40.9 years, respectively (P = 0.03). Cases were more
likely to have a history of malignancy (24.0% versus 6.2%;
P = 0.0001) and fewer were current smokers (13.2%
versus 23.3%; P = 0.2).
A nonstudy thrombophilia defect was identified in nine
cases (7%). Four had positive anticardiolipin antibodies,
and a fifth had a positive lupus anticoagulant. Of these five
women, one was homozygous for both MTHFR C677T
and A1298C, and heterozygous for the factor V polymor-
phism; one woman was homozygous for MTHFR
A1298C; one woman was homozygous for MTRR A66G;
and the remaining two women had no other identifiable
defects. Three other women displayed mild functional
protein S deficiency, of which one demonstrated homozy-
gosity for both the MTHFR A1298C and MTRR A66G
polymorphisms; one was homozygous for the MTHFR
A1298C polymorphism; and the third was homozygous for
the MTRR A66G polymorphism. One other woman was
found to have antithrombin deficiency, but had no other
detectable abnormalities.
Gene frequency
Of the six loci examined (Table 2), the population-depen-
dency of allele frequencies was known for the prothrom-
bin, factor V and MTHFR C677T genes. The frequencies
of these variant alleles among the control individuals (1.2,
1.9 and 27.0%, respectively) were within the range of
values reported for predominantly Caucasian populations.
The genotype distributions at all six loci showed no depar-
tures from those expected under the Hardy-Weinberg
equilibrium. Comparison of frequency distributions for
each allele pair showed significant differences for the pro-
thrombin, factor V and MTHFR C677T polymorphisms
(Fisher’s exact test P < 0.05). As expected, the linkage
disequilibrium was significant for each pairwise compari-
son among the three MTHFR intragenic loci (data not
shown), but not for any other pair of loci (Table 2).
Venous thromboembolism risk among all women
Among the participants, women with VTE were signifi-
cantly more likely than control individuals to be carriers of
the prothrombin polymorphism (9.3% versus 2.3%;
adjusted OR 4.3, 95% confidence interval [CI] 1.1–17.4;
Table 3). One case and no control individuals were
homozygous for the prothrombin gene defect. Similarly,
the factor V gene polymorphism was more common
among cases than control individuals (16.3% versus
3.9%; adjusted OR 3.9, 95% CI 1.4–10.8). Two cases
and no control individuals were homozygous for this
defect. Three cases (2.3%) were carriers of both the pro-
thrombin and factor V polymorphisms, for which no further
statistical analysis was conducted.
The MTRR A66G homozygous state was more common
among cases (32.6%) than control individuals (27.1%),
but not significantly (adjusted OR 1.1, 95% CI 0.6–2.2).
Homozygosity for C677T MTHFR was no more frequent
among cases (14.7%) than control individuals (10.1%;
adjusted OR 1.4, 95% CI 0.6–3.1), and neither was the
homozygous state for A1298C MTHFR (52.7% versus
53.5%; adjusted OR 1.0, 95% CI 0.6–1.7; Table 3).
Only one case and one control individual (0.8% each)
Available online http://cvm.controlled-trials.com/content/2/3/141carried the T1317C MTHFR homozygous variant
(adjusted OR 1.0, 95% CI 0.1–16.3). The presence of
any MTRR or MTHFR homozygous state was also not a
significant risk factor for VTE (adjusted OR 1.1, 95% CI
0.6–2.0).
The mean fasting plasma tHcy was significantly higher
among women with VTE (11.1 mmol/l) than control individ-
uals (6.5 mmol/l; unpaired t-test P < 0.0001; Table 1). The
95th centile tHcy value for control individuals was
11.0 mmol/l; using this latter cut-point, hyperhomocys-
teinaemia was significantly more common among cases
(35.6%) than control individuals (4.0%). The adjusted OR
was 17.8 (95% CI 4.2–74.9) for VTE in the presence of
hyperhomocysteinaemia. No significant interaction
(P > 0.50 for each) was observed between the presence
of hyperhomocysteinaemia and any MTHFR or MTRR
homozygous state.
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Table 1
Characteristics of 129 women with VTE and age-matched control individuals
Women who  Women who did not  Statistical comparison 
experienced VTE  experience VTE  between cases 
Characteristic (129 cases) (129 controls) and controls
Mean (SD) age (years) 45.8 (17.5) 40.9 (17.8) P = 0.03
Number (percentage) with deep vein thrombosis of the leg 88 (68.2) – –
Number (percentage) with deep vein thrombosis at another site 17 (13.2) – –
Number (%) with pulmonary embolism* 32 (24.8) – –
Number (%) with recurrent VTE 33 (25.6) – –
Number (%) with other thrombophilia defects† 9 (7.0) – –
Number (%) with immobilization or surgery within 3 months 23 (17.8) – –
Number (%) with malignancy within 5 years 31 (24.0) 8 (6.2) P = 0.0001
Number (%) with oestrogen exposure state‡ 44 (34.1) 43 (33.3) P = 0.9
Number (%) current cigarette smokers 17 (13.2) 30 (23.2) P = 0.2
Mean (SD) fasting plasma total homocysteine (mmol/l) 11.1 (5.6) 6.5 (3.0) P = 0.0001
Mean (SD) red-cell folate (nmol/l)$ 1121.3 (566.1) 981.9 (452.6) P = 0.05
Mean (SD) serum creatinine (mmol/l)$ 82.2 (62.8) 69.2 (10.3) P = 0.03
*Describes individuals who either experienced pulmonary embolism in isolation or in combination with a deep vein thrombosis. †Includes either a
positive test for antiphospholipid antibodies, the lupus anticoagulant, or a deficiency in protein C, protein S or antithrombin. ‡Defined as current use
of an oral contraceptive agent, hormone replacement therapy or tamoxifen, or currently pregnant or within 6 weeks postpartum. $Complete data for
serum creatinine and red-cell folate concentrations were only available for 80 case–control pairs. –, Data not applicable.
Table 2
Allele frequencies of the prothrombin, factor V, MTHFR and MTRR polymorphisms among 129 women with VTE and 129 matched
control individuals
Gene polymorphism
Prothrombin Factor  V  MTHFR MTHFR  MTHFR  MTRR 
G20210A G1691A C677T A1298C T1317C A66G
Allele Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
–/– 117 126 108 124 49 72 68 69 122 123 25 29
+/– 11 3 19 5 61 44 49 49 6 5 62 65
+/+ 1 0 2 0 19 13 12 11 1 1 42 35
Frequency 0.050 0.012 0.089 0.019 0.384 0.271 0.283 0.275 0.031 0.027 0.566 0.523
Fisher’s exact test P value 0.02 0.0007 0.008 0.92 1.0 0.4
–/–, Wildtype; +/–, heterozygote; +/+, homozygote.Venous thromboembolism risk, excluding women with
recent malignancy, immobilization or surgery
Upon excluding cases with secondary causes for VTE
(malignancy, immobilization or surgery), and their respec-
tive control individuals, 81 case–control pairs were avail-
able for analysis (Table 3). In the presence of the
prothrombin polymorphism, the adjusted OR for VTE was
7.8 (95% CI 1.0–64.2). The risk for VTE was also signifi-
cant in the presence of the factor V polymorphism
(adjusted OR 6.6, 95% CI 1.2–11.4). The risk for VTE
among homozygotes for each MTHFR and A66G MTRR
polymorphism was no higher in this subgroup, however
(P > 0.5 for each). Finally, the adjusted OR for VTE in the
presence of fasting hyperhomocysteinaemia decreased
somewhat from that observed in the main analysis
(adjusted OR 11.6, 95% CI 2.7–50.5; Table 3).
Discussion
We found that the presence of the prothrombin and factor
V gene polymorphisms and hyperhomocysteinaemia sig-
nificantly increased the risk for VTE among women. When
those with recent malignancy, surgery or immobilization
were excluded, the risk was even greater for carriers of the
prothrombin polymorphism. Although hyperhomocys-
teinaemia also increased the risk for VTE, this association
was not found for the MTRR A66G or any of the three
MTHFR gene polymorphisms.
Of the cases studied, 7% were found to have another
thrombophilia defect, such as antiphospholipid antibodies
or protein S deficiency, which was not controlled for in the
present analysis. It is unlikely that the presence of such
defects influenced the results, however, because they
were uncommon, and eight out of nine of the defects were
observed among women with the MTHFR or MTRR gene
polymorphisms, or both, none of which independently con-
ferred an increased risk for VTE.
The present study might have been limited by a referral
bias among the cases, potentially exaggerating our risk
estimates for VTE [26]. Because 25% of cases also
had recurrent VTE, these estimates might have been
further inflated. In order to evaluate this, we compared
the rates of thrombophilia gene defects in the cases
and control individuals with those in other published
case–control studies (Table 4). The prevalence of the
prothrombin gene among the control population
studied here (2.3%) was within the general limits of
other studies (range 1.0–5.4%), and our case rate
(9.3%) was similar to that of other studies (range
4.6–31.0%), albeit slightly lower than those of some
studies. Similarities in the frequencies of factor V and
C677T MTHFR gene polymorphisms were also
observed. Thus, we believe that our case and control
rates reflect those observed in other adult populations
with and without VTE. Ethnic variation, not assessed
herein, might explain some of the differences between
studies in the prevalence of these polymorphisms,
given the wide diversity of ethnicity according to geo-
graphic area [27].
Available online http://cvm.controlled-trials.com/content/2/3/141
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Table 3
Prevalence and adjusted ORs for thrombophilia among women with VTE
Excluding women 
with malignancy, 
recent surgery or 
All women immobilization*
Number (%)  Number (%) 
of cases with  controls with 
thrombophilia  thrombophilia  Crude OR  Adjusted OR† Adjusted OR‡
Thrombophilia factor factor factor (95% CI) (95% CI) (95% CI)
Prothrombin (++ or +/–) 12 (9.3) 3 (2.3) 4.3 (1.2–15.6) 4.3 (1.1–17.4) 7.8 (1.0–64.2)
Factor V (+/+ or +/–) 21 (16.3) 5 (3.9) 4.8 (1.8–13.2) 3.9 (1.4–10.8) 3.6 (1.2–11.4)
MTHFR C677T (+/+) 19 (14.7) 13 (10.1) 1.5 (0.7–3.3) 1.4 (0.6–3.1) 1.1 (0.4–2.9)
MTHFR 1298C (+/+) 68 (52.7) 69 (53.5) 1.0 (0.6–1.6) 1.0 (0.6–1.7) 1.2 (0.6–2.3)
MTRR A66G (+/+) 42 (32.6) 35 (27.1) 1.3 (0.8–2.2) 1.1 (0.6–2.2) 0.9 (0.4–2.2)
Any MTHFR (+/+) or A66G MTRR (+/+) 90 (69.8) 88 (68.2) 1.1 (0.6–1.8) 1.0 (0.6–2.0) 1.1 (0.5–2.3)
Fasting plasma hyperhomocysteinemia$ 46 (35.6) 5 (4.0) 13.7 (5.2–36.0) 17.8 (4.2–74.9) 11.6 (2.7–50.5)
*Excludes cases with immobilization or surgery within the past 3 months, or a malignancy within the past 5 years, and their respective control
individuals. †Adjusted for cigarette smoking, oestrogen exposure state and recent history of cancer. ‡Adjusted for cigarette smoking and oestrogen
exposure state. $Defined as a homocysteine concentration greater than the 95th centile value in the control group. +/+, Homozygous; +/–,
heterozygous.Although the rate of fasting hyperhomocysteinaemia found
among our control individuals (4.0%) was consistent with
those of other studies (range 4.7–5.0%; Table 4), our
case rate (35.6%) was more than twice that found by
other investigators. There are several possible reasons for
this. First, because plasma tHcy is both inversely related
to renal function [28] and directly related to age [29], the
higher tHcy levels among the cases might be partly
explained by their relatively high serum creatinine concen-
trations and older age. Second, after omitting women with
recent cancer from our subgroup analysis, the adjusted
OR dropped from 17.8 to 11.6, suggesting that malig-
nancy may play a role in tHcy metabolism, as proposed by
others [30]. Third, by excluding women with a history of
cardiovascular disease from the present study, we
probably eliminated another potential confounder (cardio-
vascular disease has been association with hyperhomo-
cysteinaemia) [16]. Finally, although we did not collect
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Table 4
Published case–control studies of the risk for VTE in the presence of polymorphisms of the prothrombin, factor V and MTHFR
C677T genes, as well as fasting hyperhomocysteinaemia
Prevalence of 
thrombophilia defect (%)
Thrombophilia defect Reference Population VTE type Cases Controls Risk estimate (95% CI)
Prothrombin gene (+/+ or +/–) [41] Men and women Any VTE 4.6 1.0 ORc 4.8 (1.5–19.8)
[42] Men and women Any VTE 14.2 4.6 ORc 3.4 (2.2–5.5)
[43] Men and women Any VTE 10.2 2.8 ORa 4.0 (1.9–8.5)
[44] Men and women Any VTE 18.5 5.4* ORa 3.6 (1.8–7.3)
[45] Men and women Any DVT 7.1 1.8 ORa 3.8 (1.1–13.2)
[20] Men and women First DVT 6.2 2.3 ORc 2.8 (1.4–5.6)
[46] Men and women First DVT 15.9 2.3 ORa 8.7 (3.8–21.4) 
[10] Pregnant women Any VTE 16.9 1.3 RRa 15.2 (4.2–52.6)
[47] Pregnant women Any VTE 31.0 4.2 ORa 10.2 (4.0–25.9)
Present study Women Any VTE 9.3 2.3 ORa 4.3 (1.1–17.4)
Factor V gene (+/+ or +/–) [41] Men and women Any VTE 12.5 1.4 ORc 2.7 (1.5–4.9)
[42] Men and women Any VTE 18.2 5.1 ORc 4.2 (2.7–6.4)
[48] Men and women Any VTE 53.0 3.3 ORc 17.4 (11.4–93.0)
[49] Men and women Any VTE 26.0 7.6 ORc 4.3 (2.3–8.1)
[43] Men and women Any VTE 19.5 3.5 ORa 6.5 (3.5–12.5)
[44] Men and women Any VTE 40.1 3.9† ORa 16.3 (8.5–31.3)
[50] Men and women DVT and PE 14.8 5.3 ORc 4.2 (1.5–10.3)
[51] Men and women Any DVT 19.5 2.9 ORc 8.0 (4.5–14.2)
[52] Men and women Any DVT 28.0 11.0 ORa 3.1 (1.7–5.5)
[53] Men and women Any DVT 23.5 6.1 ORc 4.7 (1.5–15.0)
[46] Men and women First DVT 21.1 3.2 ORa 7.8 (3.9–17.1)
[10] Pregnant women Any VTE 43.7 7.7 RRa 9.3 (5.1–16.9)
[47] Pregnant women  Any VTE 23.8 1.9 ORc 16.3 (4.8–54.9)
Present study Women Any VTE 16.3 3.9 ORa 3.9 (1.4–10.8)
MTHFR gene (+/+) [54] Men and women Any VTE 10.0 13.0 ORc 0.7 (0.5–1.0)
[55] Men and women Any VTE 28.2 17.7 ORc 1.8 (1.2–2.9)
[49] Men and women Any VTE 11.5 15.0 ORc 0.7 (0.4–1.3)
[43] Men and women Any VTE 12.7 12.3 ORa 1.0 (0.6–1.7)
[44] Men and women Any VTE 22.8 14.3 ORa 2.1 (1.2–3.7)
[56] Men and women Any VTE 12.3‡ 13.0 ORc 0.9 (0.4–2.4)
[57] Men and women Any VTE 8.0 6.4 ORc 1.4 (0.5–4.0)
[58] Men and women Any VTE 12.3 13.1 ORc 0.9 (0.4–2.3)
[53] Men and women Any DVT 7.4 10.6 ORc 0.7 (0.2–2.2)
[59] Men and women Any DVT 25.6 18.1 ORc 1.7 (1.1–2.5)
[60] Men and women Any DVT 10.0 9.9 ORc 1.0 (0.7–1.5)
[46] Men and women First DVT 20.5 21.0 ORa 1.0 (0.7–1.2)
[47] Pregnant women Any VTE 28.6 16.0 ORc 2.1 (1.0–4.5)
Present study Women Any VTE 14.7 10.1 ORa 1.4 (0.6–3.1) 
Fasting hyper-homocysteinaemia [24] Men and women Any VTE 12.5 4.7 ORp 3.0 (2.1–4.2)$
[55] Men and women Any VTE 16.0 5.0 ORc 3.6 (1.8–7.3)
Present study Women Any VTE 35.6 4.0 ORa 17.8 (4.2–74.9)
*Describes the +/– genotype. †Describes the +/+ genotype. ‡Describes the prevalence of the MTHFR C677T +/+ state among individuals with
factor V. $Comprises pooled data from nine observational studies. DVT, deep vein thrombosis; +/+, homozygous; +/–, heterozygous; ORa,
adjusted OR; ORc, crude OR; ORp, pooled OR; RRa, adjusted relative risk.data on serum vitamin B12, it has been demonstrated that
both measured vitamin B12 [31] and its supplementation
[32] probably have little influence on plasma tHcy concen-
tration relative to that of folate, which appeared to be
higher among the cases than the control individuals in
whom it was measured.
A meta-analysis of 23 observational studies [33] failed to
demonstrate an association between MTHFR 677T
homozygosity and arterial disease (pooled OR 1.1, 95%
CI 0.9–1.4). Similarly, our data and those of others
(Table 4) suggest that the MTHFR polymorphisms do not
heighten the risk for VTE. Furthermore, we found no signif-
icant interaction between MTHFR homozygosity and
hyperhomocysteinaemia. Thus, we recommend that clini-
cal testing for currently identified polymorphisms in the
MTHFR gene be postponed in the evaluation of VTE risk
outside of the research setting. A further understanding of
the interaction between the combination of hyperhomo-
cysteinaemia and other gene polymorphisms, such as
factor V [34] and prothrombin, is needed.
If hyperhomocysteinaemia is a true causative risk factor for
a first [24] or subsequent [35] VTE event, then the mecha-
nisms responsible for tHcy elevation and, hence, venous
thrombosis require further elucidation. Newly isolated
polymorphisms, such as MTRR A66G, may contribute to
the development of VTE, but we found no such associa-
tion in the group studied here. In the meantime, we expect
that clinical trials of tHcy reduction [36], in addition to
future work in the field of molecular and genetic epidemiol-
ogy, are the next logical steps.
Others have evaluated the influence of nongenetic factors
on the risk for VTE. For example, in a post-trial analysis by
the Heart Estrogen Replacement Study (HERS) investiga-
tors [8], the risk for VTE was increased among women
with lower-extremity fractures (adjusted relative hazard
[RH] 18.1, 95% CI 5.4–60.4] or cancer (RH 3.9, 95% CI
1.6–9.4), or who had had inpatient surgery within the pre-
ceding 90 days (RH 4.9, 95% CI 2.4–9.8). Even limited
periods of immobilization, such as a short illness or minor
surgery or injury, appear to increase the risk for deep vein
thrombosis (OR 2.9, 95% CI 1.5–5.4) [37]. We therefore
conducted a subgroup analysis that excluded women with
malignancy, recent surgery, or immobilization. Although we
might expect that certain thrombophilia markers confer the
greatest relative risk for VTE in the absence of other risk
factors [4], as was the case for the prothrombin polymor-
phism, we cannot explain why this was not so for factor V.
Future research should further explore the interplay
between hereditary and acquired VTE risk factors.
Clinicians face a dilemma in deciding which women
should be screened for these and other thrombophilia
markers. It would seem both imprudent and costly to
investigate those who develop VTE in the presence of
active malignancy, because anticoagulant therapy is likely
to be continued indefinitely [38]. However, among women
who experience VTE either in the absence of any risk
factors, while taking hormone replacement therapy [8,39]
or oral contraceptives [6,7], or during pregnancy and the
puerperium [10,11], a thrombophilia assessment may be a
sensible option. Specifically, others have demonstrated
that oestrogen use and activated protein C resistance
have a synergistic effect on the risk for VTE (OR 13.3,
95% CI 4.3–41.0) [39]. It is least clear whether screening
is beneficial in an otherwise healthy woman who develops
VTE after surgery or a fracture of the lower extremity
[5,40]. Hopefully these issues can be resolved through
ongoing research and expert consensus.
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